Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
In this post hoc analysis of the CLEAR Outcomes randomized clinical trial, investigators evaluated whether bempedoic acid reduces the risk of venous thromboembolism (VTE) in statin-intolerant patients at high cardiovascular risk.
A total of 13,970 participants (mean age 65.5 years; 48.2% women) were randomized to bempedoic acid 180 mg daily or placebo and followed for a median of 40.6 months.
During follow-up, 106 VTE events occurred.
Bempedoic acid was associated with a significant 42% relative reduction in VTE compared with placebo (39 vs 67 events; HR 0.58, 95% CI 0.39–0.86; P=0.006).
Consistent benefits were observed for both major components of VTE: deep vein thrombosis (HR 0.56, 95% CI 0.31–0.996; P=0.045) and pulmonary embolism (HR 0.61, 95% CI 0.37–0.996; P=0.046).
These findings extend previous evidence suggesting that lipid-lowering therapies may provide protection beyond atherosclerotic cardiovascular disease, potentially reducing thrombotic events through anti-inflammatory effects, lipoprotein(a) reduction, and enhanced clearance of coagulation factors.
Importantly, the observed reduction in VTE persisted even after accounting for major cardiovascular events.
Although limited by its post hoc design and the relatively small number of VTE events, this analysis suggests that bempedoic acid may offer an additional clinical benefit in statin-intolerant patients by lowering both cardiovascular and venous thromboembolic risk.
These results should be considered hypothesis-generating and warrant prospective confirmation.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera
-
Sep 5, 2026, 05:48Punit Mathur: From Leg Pain to Life-Threatening Pulmonary Embolism
-
Sep 5, 2026, 05:44Patrick Stonich: Identifying Missed Signs of Postoperative Pulmonary Embolism in Medical Record Reviews
-
Sep 5, 2026, 05:38Tom Van den Hoek: Warburg Effect Mimicking Refractory Shock in Cancer-Associated PE
-
Sep 5, 2026, 05:11Shinya Goto: Targeted Thrombolysis for High Risk Pulmonary Embolism
-
Sep 5, 2026, 04:56Opportunities for the Next Generation of Hematologists – American Society of Hematology
-
Sep 5, 2026, 04:51Samuel Nwokolo: The Bone Marrow Factory – Anatomy of Blood Production
-
Sep 5, 2026, 04:37Maryam Alaa Alsaid: Diagnostic Puzzle of Sickle Beta Thalassemia
-
Sep 5, 2026, 04:16Key Cardiovascular Insights from ESC Congress